Loading...
XJPX
4591
Market cap16mUSD
Jul 10, Last price  
74.00JPY
1D
-3.90%
1Q
-13.95%
Jan 2017
-89.49%
IPO
-96.01%
Name

Ribomic Inc

Chart & Performance

D1W1MN
XJPX:4591 chart
P/E
—
P/S
880.31
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.06%
Rev. gr., 5y
-49.57%
Revenues
3m
+42.38%
229,065,000168,613,000151,220,000479,871,000121,911,00093,773,00064,727,0007,949,000121,385,00091,963,00080,909,00065,968,99902,107,0003,000,000
Net income
-1.15b
L+12.41%
-313,404,000-276,249,000-211,831,00010,298,000-323,313,000-646,603,000-753,048,000-836,624,000-855,042,000-1,187,194,000-1,684,754,000-1,653,002,000-1,024,237,000-1,018,939,000-1,145,360,000
CFO
-1.11b
L+11.42%
-153,240,000-162,525,000134,584,000-324,703,000-706,894,000-694,797,000-830,464,000-902,288,000-1,149,038,000-1,499,224,000-1,708,626,000-932,757,000-996,966,000-1,110,863,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.
URL
https://www.ribomic.com/
IPO date
Sep 25, 2014
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT